Evidence map›Paper›PMID 37410308›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2023

Overall Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitor Luseogliflozin Versus Dipeptidyl-Peptidase 4 Inhibitors: Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT study).

Masahiro Sugawara, Masahiro Fukuda, Ichiro Sakuma, Yutaka Wakasa, Hideaki Funayama, Akira Kondo, Naoki Itabashi, Yasuyuki Maruyama, Takashi Kamiyama, Yasunori Utsunomiya and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 9 institutions in 1 country.

Masahiro SugawaraSugawara Clinic, 3-9-16 Syakujii-machi, Nerima, Tokyo, 177-0041, Japan. ms@sugawara.or.jp.ORCID http://orcid.org/0000-0002-3634-5508
Masahiro FukudaFukuda Clinic, 1-6-1, Miyahara, Yodogawa, Osaka-shi, Osaka, 532-0003, Japan.
Ichiro SakumaCaress Sapporo Hokko Memorial Clinic, Kita-17, Higashi-8, 1-15, Sapporo, Hokkaido, 065-0027, Japan.
Yutaka WakasaWakasa Medical Clinic, 3-16-25, Sainen, Kanazawa, Ishikawa, 920-0024, Japan.
Hideaki FunayamaFunayama Medical Clinic, 1-13-14 Tomioka, Koto, Tokyo, 135-0047, Japan.
Akira KondoKondo Hospital, 1-6-25 Nishi-Shinhama-cho, Tokushima, 770-8008, Japan.
Naoki ItabashiItabashi Clinic, 815-1, Higashi-Ushigaya, Koga, Ibaraki, 306-0232, Japan.
Yasuyuki MaruyamaIwatsuki-Minami Hospital, 2256 Kuroya Iwatsuki, Saitama-shi, Saitama, 339-0033, Japan.
Takashi KamiyamaKamiyama Clinic, 5-21-18, Takanodai, Nerima, Tokyo, 177-0033, Japan.
Yasunori UtsunomiyaHoya Hospital, 4-50-15 Minami-Oizumi, Nerima, Tokyo, 178-0064, Japan.
Akira YamauchiSuruga Clinic, 9-23, Shoufuku-cho, Shimizu, Shizuoka, Shizuoka, 424-0855, Japan.
Hidenori YoshiiDepartment of Diabetes and Endocrinology, Juntendo Tokyo Koto Geriatric Medical Center, 3-3-20 Shinsuna, Koto, Tokyo, 136-0075, Japan.
Hirokazu YamadaSoiken Inc., Chiyoda, Tokyo, 101-0052, Japan.
Koichi MochizukiMochizuki Naika Clinic, 4-5, Aioi-cho, Itabashi, Tokyo, 174-0044, Japan.
J-SELECT study investigators
Futaba clinic · JPSapporo Minami Hospital · JPEiken Chemical (Japan) · JPHokko Memorial Hospital · JPHoya (Japan) · JPKanazawa Medical Center · JPKoto Hospital · JPShimizu (Japan) · JPTamagawa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionEvidence of a direct comparison between dipeptidyl-peptidase 4 inhibitors (DPP-4is) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) remains lacking, and no clear treatment strategy or rationale has been established using these drugs. This study aimed to compare the overall efficacy and safety of DPP-4is and the SGLT2i luseogliflozin in patients with type 2 diabetes mellitus (T2DM).

methodsPatients with T2DM who had not used antidiabetic agents or who had used antidiabetic agents other than SGLT2is and DPP-4is were enrolled in the study after written informed consent had been obtained. The enrolled patients were subsequently randomly assigned to either the luseogliflozin or DPP-4i group and followed up for 52 weeks. The primary (composite) endpoint was the proportion of patients who showed improvement in ≥ 3 endpoints among the following five endpoints from baseline to week 52: glycated hemoglobin (HbA1c), weight, estimated glomerular filtration rate (eGFR), systolic blood pressure, and pulse rate.

resultsA total of 623 patients were enrolled in the study and subsequently randomized to either the luseogliflozin or DPP-4i groups. The proportion of patients who showed improvement in ≥ 3 endpoints at week 52 was significantly higher in the luseogliflozin group (58.9%) than in the DPP-4i group (35.0%) (p < 0.001). When stratified by body mass index (BMI) (< 25 or ≥ 25 kg/m

conclusionThis study showed the overall efficacy of luseogliflozin compared with DPP-4is over the mid/long term, regardless of BMI or age. The results suggest the importance of assessing multiple aspects regarding the effects of diabetes management. TRIAL REGISTRATION NUMBER: jRCTs031180241.

Indexed as

Composite endpointDipeptidyl-peptidase 4 inhibitorEstimated glomerular filtration rateGlycated hemoglobinLuseogliflozinOverall efficacyPulse rateSodium-glucose cotransporter 2 inhibitorSystolic blood pressureWeight

Identifiers

PMID37410308
PMCPMC10363101
OpenAlexW4383302500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.